Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
RESEARCH TOOLSreports
Holding NRSN?
Track your performance easily
NRSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.51 - $2.33
Previous Close$0.88
Volume106.51K
Average Volume (3M)239.33K
Market Cap
$18.17M
Enterprise Value$15.60M
Total Cash (Recent Filing)$2.64M
Total Debt (Recent Filing)$73.00K
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 27, 2024EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding19,470,000
10 Day Avg. Volume109,421
30 Day Avg. Volume239,329
Standard Deviation0.48
R-Squared0.03
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)-9.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$3.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Neurosense Therapeutics Ltd. News
PremiumCompany Announcements
NeuroSense Therapeutics Secures Continued Nasdaq Listing
PremiumCompany Announcements
Neurosense Therapeutics Secures $30 Million Equity Deal
PremiumCompany Announcements
NeuroSense Completes Key ALS Trial Phase
PremiumCompany Announcements
NeuroSense Therapeutics Advances ALS Drug Development Plans
PremiumCompany Announcements
NeuroSense’s PrimeC Shows Potential in ALS Treatment
PremiumCompany Announcements
NeuroSense Targets Key ALS Drug Market in CanadaOwnership Overview
26.88%
Insiders
0.06% Mutual Funds
0.61% Other Institutional Investors
72.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $0.51 and its highest was $2.33 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is Nov 27, 2024 which is today.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Aug 28, 2024. The company reported -$0.185 earnings per share for the quarter, the consensus estimate of -$0.185 by $0.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate is -$0.11.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 20,709,480 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$0.185 in its last earnings report, expectations of -$0.185. Following the earnings report the stock price went down -4.054%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Among the largest hedge funds holding Neurosense Therapeutics Ltd.’s share is Woodline Partners LP. It holds Neurosense Therapeutics Ltd.’s shares valued at N/A.
---
Neurosense Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (233.33% Upside)
$3.00 (233.33% Upside)
Hedge Fund Trend
Decreased
By 19.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-76.60%
Trailing 12-Months
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
---
NRSN Stock 12 Month Forecast
Average Price Target
$3.00
▲(233.33% Upside)
Technical Analysis
Best Analysts Covering NRSN
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-22.32%
reiterated a buy rating 2 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -22.32% per trade.
---